Cargando…

Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis

Detalles Bibliográficos
Autores principales:	Metz, Imke, Rieckmann, Peter, Kallmann, Boris-Alexander, Brück, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977646/ https://www.ncbi.nlm.nih.gov/pubmed/27503238 http://dx.doi.org/10.1186/s40478-016-0352-1

Ejemplares similares

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis
por: Akgün, Katja, et al.
Publicado: (2018)

Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis
por: Alamo, Angela, et al.
Publicado: (2019)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy
por: Metz, Imke, et al.
Publicado: (2011)

Comment on “Alemtuzumab improves cognitive processing speed in active multiple sclerosis – a longitudinal observational study”
por: Asadollahzade, Elnaz, et al.
Publicado: (2022)

Alemtuzumab in the treatment of multiple sclerosis
por: Fernandez, Óscar
Publicado: (2014)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Disseminated Necrotizing Leukoencephalopathy Complicating Septic Shock in an Immunocompetent Patient
por: Gaspar-da-Costa, Pedro, et al.
Publicado: (2017)

Long-term efficacy of alemtuzumab in polymyositis
por: Ruck, Tobias, et al.
Publicado: (2015)

Severe autoimmune intravascular hemolytic anemia in patients receiving alemtuzumab for multiple sclerosis
por: Sharma, Parth, et al.
Publicado: (2022)

Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod
por: Sinnecker, Tim, et al.
Publicado: (2016)

Mycobacterium haemophilum Infection after Alemtuzumab Treatment
por: Kamboj, Mini, et al.
Publicado: (2008)

Reply: Comment on alemtuzumab and inclusion body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2010)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

Necrotizing infundibulo-hypophysitis: an entity too rare to be true?
por: Gutenberg, Angelika, et al.
Publicado: (2011)

Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab
por: Jung, Chul Won, et al.
Publicado: (2016)

Disseminated Cryptococcosis with Widespread Necrotizing Fasciitis and Cryptococcemia Occurring in an Immunosuppressed Patient
por: Li, Feng, et al.
Publicado: (2014)

Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons
por: Singh, Shailender, et al.
Publicado: (2013)

Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma
por: Liu, Shanshan, et al.
Publicado: (2023)

Month of Birth and the Incidence of Multiple Sclerosis in Southern Iran
por: Nikseresht, Alireza, et al.
Publicado: (2014)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Role of Monoclonal Antibody "Alemtuzumab" in the Treatment of Multiple Sclerosis
por: Nosher, Sadia, et al.
Publicado: (2021)

Comments on the review article ‘Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades’
por: Berg‐Hansen, P., et al.
Publicado: (2015)

Histiocytosis-related cerebellar leukoencephalopathy
por: Ekici, Bariş, et al.
Publicado: (2011)

Reversible posterior leukoencephalopathy syndrome
por: Raina, Sujeet, et al.
Publicado: (2012)

Increased interleukin-27 cytokine expression in the central nervous system of multiple sclerosis patients
por: Lalive, Patrice H., et al.
Publicado: (2017)

CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study
por: Häusler, Darius, et al.
Publicado: (2021)

Cell type-specific Nrf2 expression in multiple sclerosis lesions
por: Licht-Mayer, Simon, et al.
Publicado: (2015)

EBV related cerebral lymphoma in a leukemia patient treated with alemtuzumab
por: van de Langerijt, B., et al.
Publicado: (2010)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
por: Babij, Rachel, et al.
Publicado: (2015)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
por: Dubey, Divyanshu, et al.
Publicado: (2015)

Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations
por: Dörr, Jan, et al.
Publicado: (2016)

The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis
por: Rolla, Simona, et al.
Publicado: (2020)

Thyroid Autoimmunity Following Alemtuzumab Treatment in Multiple Sclerosis Patients
por: Kazakou, Paraskevi, et al.
Publicado: (2021)

An Unusual Case of Adult-Onset Still's Disease with Hemophagocytic Syndrome, Necrotic Leukoencephalopathy and Disseminated Intravascular Coagulation
por: Namas, Rajaie, et al.
Publicado: (2014)

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
por: Havrdova, Eva, et al.
Publicado: (2017)

Toxic Leukoencephalopathy and Hypokalemia Due to Exposure to Trimethyltin
por: Wang, Zigao, et al.
Publicado: (2017)

Delayed Post-hypoxic Leukoencephalopathy with Neuroradiological Recovery
por: Manjunath, Varun, et al.
Publicado: (2021)

Necrotic xanthogranuloma with disseminated annular lesions()()
por: Fasciani, Isaura Azevedo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lghcs5k1ne879t933e6ij71rrq